Nuveen LLC Takes Position in Aquestive Therapeutics, Inc. $AQST

Key Points

• Nuveen LLC has made a new investment of approximately $686,000 in Aquestive Therapeutics, acquiring 236,473 shares of the company during the first quarter.
• Analysts have a consensus rating of "Moderate Buy" for AQST, with a price target of $10.14, with seven analysts rating the stock as a Buy.
• Aquestive Therapeutics reported a larger-than-expected loss per share of ($0.14) in its recent earnings, with revenues of $10 million for the quarter, below the consensus estimate.

Nuveen LLC purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 236,473 shares of the company's stock, valued at approximately $686,000. Nuveen LLC owned 0.24% of Aquestive Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Janney Montgomery Scott LLC lifted its position in Aquestive Therapeutics by 7.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company's stock valued at $3,073,000 after acquiring an additional 75,275 shares in the last quarter. Bank of America Corp DE lifted its stake in Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after purchasing an additional 621,614 shares during the last quarter. Northern Trust Corp increased its position in shares of Aquestive Therapeutics by 3.1% during the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company's stock worth $2,135,000 after buying an additional 18,199 shares during the period. Harvey Capital Management Inc. grew its holdings in Aquestive Therapeutics by 86.8% in the first quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock worth $1,449,000 after purchasing an additional 232,180 shares during the period. Finally, Stifel Financial Corp grew its holdings in shares of Aquestive Therapeutics by 315.4% during the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock valued at $1,419,000 after buying an additional 302,617 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST traded down $0.34 during mid-day trading on Monday, hitting $5.09. The stock had a trading volume of 2,534,072 shares, compared to its average volume of 1,616,245. The firm's 50 day moving average is $3.98 and its 200 day moving average is $3.25. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $5.80. The stock has a market capitalization of $507.08 million, a price-to-earnings ratio of -7.25 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Zacks Research raised shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer increased their price objective on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday. Finally, Lifesci Capital raised shares of Aquestive Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and a consensus target price of $10.29.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.